Embla Medical hf.
OSSFF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $855 | $786 | $719 | $719 |
| % Growth | 8.8% | 9.3% | -0% | – |
| Cost of Goods Sold | $355 | $331 | $311 | $298 |
| Gross Profit | $500 | $454 | $408 | $421 |
| % Margin | 58.5% | 57.8% | 56.8% | 58.6% |
| R&D Expenses | $35 | $33 | $29 | $27 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $352 | $334 | $293 | $299 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $387 | $367 | $323 | $325 |
| Operating Income | $113 | $87 | $85 | $96 |
| % Margin | 13.2% | 11.1% | 11.8% | 13.3% |
| Other Income/Exp. Net | -$22 | -$11 | -$29 | -$9 |
| Pre-Tax Income | $91 | $76 | $56 | $87 |
| Tax Expense | $22 | $17 | $13 | $21 |
| Net Income | $68 | $58 | $43 | $64 |
| % Margin | 8% | 7.4% | 5.9% | 8.9% |
| EPS | 0.16 | 0.14 | 0.1 | 0.15 |
| % Growth | 14.3% | 40% | -33.3% | – |
| EPS Diluted | 0.16 | 0.14 | 0.1 | 0.15 |
| Weighted Avg Shares Out | 427 | 420 | 418 | 422 |
| Weighted Avg Shares Out Dil | 427 | 420 | 418 | 423 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $3 | $1 | $0 |
| Interest Expense | $25 | $21 | $13 | $13 |
| Depreciation & Amortization | $56 | $50 | $49 | $52 |
| EBITDA | $168 | $143 | $118 | $151 |
| % Margin | 19.6% | 18.2% | 16.4% | 20.9% |